12/16/2022 | BKCVDDEMHY | Prospect News reports six new defaults for Dec. 8-Dec. 14
|
12/12/2022 | BKCVDD | Clovis Oncology files Chapter 11 bankruptcy, plans to sell assets
|
11/9/2022 | CVDD | Clovis Oncology bankruptcy in near term looks ‘increasingly probable’
|
11/25/2020 | CVLM | Clovis enters exchange agreement with holder of 4.5% convertibles
|
11/5/2020 | CVLM | Clovis enters exchange agreement with holder of 4.5% convertibles
|
4/20/2020 | CV | Market Commentary: 2U convertible offering eyed; Scorpio Tankers expands as oil collapses; Clovis active
|
4/14/2020 | CVLM | Clovis enters exchange agreement with holder of 2.5% convertibles
|
1/7/2020 | CV | Market Commentary: Luckin Coffee, Alibaba exchangeables on deck; Apellis expands ‘massively’; Clovis mixed
|
1/7/2020 | CVLM | Clovis to buy back $123.42 million 4.5% convertibles due 2024
|
1/7/2020 | CV | Market Commentary: Morning Commentary: Apellis expands ‘massively’; Clovis buys back convertible notes
|
12/2/2019 | CV | Market Commentary: Convertibles secondary slow; Intercept, Clovis bull run continues; Akamai notes active
|
8/22/2019 | CV | Clovis partial greenshoe lifts 4.5% convertibles to $263 million
|
8/9/2019 | CV | Market Commentary: Convertibles issuance tops $3 billion for week, Clovis, BlackLine expand; Ironwood drops
|
8/9/2019 | CV | Market Commentary: Morning Commentary: Clovis, BlackLine price; primary rounds out busiest week of year
|
8/8/2019 | CVLM | Clovis Oncology to buy back $190.3 million 2.5% convertibles Aug. 13
|
8/8/2019 | CV | New Issue: Clovis Oncology prices $250 million 4.5% five-year convertibles, up 25%
|
8/8/2019 | CV | Market Commentary: Morning Commentary: BlackLine, Clovis Oncology convertibles on tap; four deals price
|
8/7/2019 | CV | Market Commentary: Alteryx, Ironwood, Mesa Labs eyed; CorEnergy, BlackLine, Clovis on tap; Snap skyrockets
|
8/7/2019 | CV | Clovis Oncology talks $225 million five-year convertibles to yield 4%-4.5%, up 25%-30%
|
7/23/2019 | CV | Market Commentary: Tesla in focus pre-earnings; recent convertible sees large block trade; Clovis active
|
6/17/2019 | CV | Market Commentary: Change Healthcare on tap; DISH Network expands; Array skyrockets outright on buyout
|
6/17/2019 | CV | Market Commentary: Morning Commentary: Secondary trading light; health care sector boosted by Array buyout
|
1/3/2019 | CV | Market Commentary: Apple suppliers Microchip Technology, Western Digital notes active; Ensco better bid
|
12/4/2018 | CV | Market Commentary: RH ‘explores’ new convertible offering, existing notes mixed; Clovis expansion continues
|
12/3/2018 | CV | Market Commentary: Tesaro convertibles active, up on buyout by GlaxoSmithKline; iQIYI, Liberty Media gain
|
11/6/2018 | CV | Market Commentary: Booking Holdings convertibles dominate; Invacare slips; Clovis up; Weatherford active
|
10/31/2018 | CV | Market Commentary: Clovis convertibles clobbered; Exact Sciences, FireEye improve; Weatherford rebounds
|
10/22/2018 | CV | Market Commentary: Weibo improves on China stock rally; Clovis convertibles mixed; Hope Bancorp drops
|
5/1/2018 | CV | Market Commentary: Transocean convertibles in spotlight; Marriott, Arconic remain in focus; EFII active
|
4/30/2018 | CV | Market Commentary: Marriott Vacations active on ILG acquisition; Arconic expands; Molina notes volatile
|
4/23/2018 | CV | Market Commentary: JPMorgan on tap; Clovis contraction continues; Insmed improves; Ctrip.com, NXP active
|
4/20/2018 | CV | Market Commentary: New convertible paper quiet; Clovis contracts; Ionis, NXP in focus in secondary market
|
4/20/2018 | CV | Market Commentary: Morning Commentary: New convertible paper quiet in early trading; Clovis moves lower
|
4/18/2018 | CV | Market Commentary: Paratek, Ship Finance convertibles on tap; Jersey Industries, Deutsche Bank deals eyed
|
4/18/2018 | CV | Market Commentary: Morning Commentary: Jersey Industries, Deutsche Bank deals on tap; Red Hat active
|
4/17/2018 | CV | Market Commentary: South Jersey, Deutsche on tap; Clovis convertibles ‘well received’; oil still catching bids
|
4/17/2018 | CV | Market Commentary: Morning Commentary: Clovis convertibles ‘well received,’ expand on market debut
|
4/16/2018 | CV | New Issue: Clovis prices upsized $300 million seven-year convertibles to yield 1.25%, up 40%
|
4/16/2018 | CV | Market Commentary: Clovis Oncology deal looks ‘cheap,’ existing convertible trades down; Lumentum drops
|
4/16/2018 | CV | Market Commentary: Morning Commentary: Clovis Oncology launches $200 million offering; deal looks ‘cheap’
|
4/16/2018 | CV | Clovis talks $200 million seven-year convertible notes to yield 1% to 1.5%, up 35% to 40%
|
6/20/2017 | CV | Market Commentary: Energy names sink with drop in oil prices; Tesla edges up; Synaptics, Teladoc notes on tap
|
6/20/2017 | CV | Market Commentary: Morning Commentary: Energy names sink outright with lower oil prices; Clovis Oncology quiet, gains
|
6/19/2017 | CV | Market Commentary: Clovis Oncology convertibles jump over 25 points on positive trial data; biotech follows
|
6/19/2017 | CV | Market Commentary: Morning Commentary: Clovis Oncology dominates trading, convertibles jump over 25 points on data
|
1/5/2017 | CV | Market Commentary: Colony Starwood’s new deal trades above par; Michelin taps the market; Clovis on the rise
|
8/24/2016 | CV | Market Commentary: Dycom lower outright, adds on swap; Clovis eyed for potential drug approval; REITs for sale
|
8/24/2016 | CV | Market Commentary: Morning Commentary: Dycom lower outright but expands on swap; Clovis shares higher on drug outlook
|
8/22/2016 | CV | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
6/29/2016 | CV | Market Commentary: Tesaro surges after positive drug data; Tesla lower; Intercept Pharmaceuticals on tap
|
6/29/2016 | CV | Market Commentary: Morning Commentary: Tesaro surges after positive drug study data; Tesla lower; equities on the rise
|
4/13/2016 | CV | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
4/12/2016 | CV | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Morning Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake gains
|
11/17/2015 | CV | Market Commentary: SunEdison gaps lower again; new Black Hills mandatory looks cheap; Clovis slide continues
|
11/17/2015 | CV | Market Commentary: Morning Commentary: Planned Black Hills mandatory looks 2% cheap; Clovis Oncology slide continues
|
11/16/2015 | CV | Market Commentary: Convertibles steady after Paris terror attacks; Clovis collapses on drug-review setback
|
11/16/2015 | CV | Market Commentary: Morning Commentary: Clovis collapses on drug-review setback; Vipshop extends losses; Illumina up
|
4/13/2015 | CV | Market Commentary: Clovis jumps outright, on swap; Medicines, Horizon Pharma trade; Asian internet names eyed
|
10/28/2014 | CV | Market Commentary: Twitter drops outright, mixed to lower on hedge; Medicines opens up; Synergy to price
|
9/9/2014 | CV | Clovis greenshoe exercised, lifts 2.5% convertibles to $287.5 million
|
9/4/2014 | CV | Market Commentary: New Clovis, Depomed upsized, add on debut; Electronics For Imaging edges up; Teslas mixed
|
9/4/2014 | CV | Market Commentary: Morning Commentary: Clovis, Depomed add with underlying shares mixed; Electronics For Imaging gains
|
9/3/2014 | CV | New Issue: Clovis Oncology prices upsized $250 million 2.5% seven-year convertibles, up 37.5%
|
9/3/2014 | CV | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
9/3/2014 | CV | Market Commentary: Morning Commentary: New deals in focus; Clovis Oncology shares sharply lower; Exelixis slips
|
9/2/2014 | CV | Clovis Oncology plans $200 million seven-year convertibles to yield 2.5%-3%, up 32.5%-37.5%
|
9/2/2014 | CV | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|